Aslan Pharmaceuticals Asset Turnover Over Time
ASLN Stock | USD 0.51 0.03 5.56% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Aslan Pharmaceuticals Performance and Aslan Pharmaceuticals Correlation. Aslan |
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.75) | Revenue Per Share 0.746 | Return On Assets (0.64) | Return On Equity (4.27) |
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Asset Turnover Analysis
Compare Aslan Pharmaceuticals and related stocks such as Monte Rosa Therapeutics, NewAmsterdam Pharma, and Inventiva Sa Asset Turnover Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
GLUE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
NAMS | 0.1834 | 0.1834 | 0.1834 | 0.1834 | 0.1834 | 0.1834 | 0.1834 | 0.1834 | 0.1834 | 0.1834 | 0.1834 | 0.1834 | 0.1834 | 0.0406 | 0.0386 |
IVA | 0.0352 | 0.0352 | 0.0352 | 0.0352 | 0.0449 | 0.0805 | 0.1933 | 0.0877 | 0.0401 | 0.1229 | 0.0027 | 0.0344 | 0.105 | 0.2528 | 0.27 |
CGEM | 0.0433 | 0.0433 | 0.0433 | 0.0433 | 0.0433 | 0.0433 | 0.0433 | 0.0433 | 0.0433 | 0.0433 | 0.0433 | 0.0433 | 0.0433 | 0.039 | 0.0346 |
CMPX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
GPCR | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
IOBT | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
ERAS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
LYRA | 0.0491 | 0.0491 | 0.0491 | 0.0491 | 0.0491 | 0.0491 | 0.0491 | 0.0491 | 0.0491 | 0.0052 | 0.0052 | 0.0052 | 0.0124 | 0.0109 | 0.0213 |
ANEB | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
MLYS | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
ANTX | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
AVTE | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
ADAG | 0.0278 | 0.0278 | 0.0278 | 0.0278 | 0.0278 | 0.0278 | 0.0278 | 0.0278 | 0.0278 | 0.0045 | 0.0057 | 0.0537 | 0.061 | 0.1565 | 0.16 |
ACRV | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
AGIO | 0.1123 | 0.1123 | 0.1832 | 0.127 | 0.1329 | 0.1407 | 0.1129 | 0.07 | 0.1099 | 0.1324 | 0.2382 | 0.0115 | 0.0115 | 0.0286 | 0.0272 |
ASMB | 0.0533 | 0.0533 | 0.0533 | 0.0533 | 0.0533 | 0.0533 | 0.0533 | 0.0533 | 0.0552 | 0.047 | 0.2793 | 0.0327 | 0.0521 | 0.0469 | 0.0693 |
ACHL | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
CTMX | 0.0626 | 0.0626 | 0.0626 | 0.0626 | 0.0695 | 0.0391 | 0.0755 | 0.1801 | 0.1302 | 0.1685 | 0.2798 | 0.205 | 0.2038 | 0.4934 | 0.52 |
TIL | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 4.0E-4 | 3.0E-4 |
Aslan Pharmaceuticals and related stocks such as Monte Rosa Therapeutics, NewAmsterdam Pharma, and Inventiva Sa Asset Turnover description
The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.My Equities
My Current Equities and Potential Positions
Aslan Pharmaceuticals Ltd | ASLN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Location | Singapore |
Exchange | NASDAQ Exchange |
USD 0.51
Check out Aslan Pharmaceuticals Performance and Aslan Pharmaceuticals Correlation. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Aslan Stock analysis
When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stocks Directory Find actively traded stocks across global markets | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Aslan Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.